Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 62Myelodysplastic Syndromes 33Leukemia, Myelomonocytic, Chronic 16Leukemia 16Recurrence 9Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myelomonocytic, Acute 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Monocytic, Acute 5Hodgkin Disease 5Myeloproliferative Disorders 4Congenital Abnormalities 4Anemia, Refractory, with Excess of Blasts 4Thrombocythemia, Essential 3Primary Myelofibrosis 3Polycythemia Vera 3Lymphoma 3Blast Crisis 3Triple Negative Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm, Residual 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Extranodal Extension × Decitabine × Clear all
NCT05816746 2023-05-09

Decitabine and Anti-PD-1 in R/R DLBCL

Chinese PLA General Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Extranodal Extension, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡